Product logins

Find logins to all Clarivate products below.


Binge Eating Disorder – Epidemiology – Binge Eating Disorder

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of BED for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

Clarivate Epidemiology’s BED forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BED over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 BED patient populations, as follows:

  • Total lifetime prevalent cases of BED.
  • Total 12-month prevalent cases of BED.
  • Total lifetime prevalent cases of mild BED.
  • Total lifetime prevalent cases of moderate BED.
  • Total lifetime prevalent cases of severe BED.
  • Total lifetime prevalent cases of extreme BED.
  • Total lifetime prevalent cases of BED with depression.
  • Total lifetime prevalent cases of BED with anxiety disorder.
  • Total lifetime prevalent cases of BED with bipolar disorder.
  • Total lifetime prevalent cases of BED with attention-deficit/hyperactivity disorder.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…